About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, April 13th, 2015

The QualityStocks
Daily Stock List


Medizone International, Inc. (MZEI)

PennyStocks24, Stock Brain, HEROSTOCKS, VIP STOCK ALERTS, Stockhunter.us, and Liquid Pennies reported previously on Medizone International, Inc. (MZEI), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.

Medizone International, Inc. and its’ subsidiaries have been a development stage company conducting research into the use of ozone in the disinfection of surgical and other medical treatment facilities and in other applications. During 2012, the Company emerged from the development stage. It began to sell its patented ozone disinfection system, AsepticSure®. Medizone International is based in Sausalito, California.

The AsepticSure® hospital sterilization system is a portable, affordable, easily operated system. It can be used by trained maintenance staff and it is placed in the center of the room to be cleaned.  Vents and doors are then sealed with an easily and cleanly removable 3M-tape product.

The system is turned on from outside of the room by way of a remote wireless computer interface. The room is filled with a unique and patented gas formula that is ozone-based to specific humidity and charge strength. The sterilization process is remotely turned off after the charge period and a separate technology is employed that restores the atmosphere inside the room to Environmental Protection Agency (EPA) standards.

Medizone International’s BSL2A certified laboratory is at Innovation Park, Queen’s University in Kingston, Ontario. It provides a primary research and development platform for the Company.

After December 31, 2012, Singapore issued Medizone International its Health Care Patent. The Company considers this significant for its business growth in Asia. Medizone believes Singapore could become a lucrative market for AsepticSure® sales. The medical system in Singapore looks to distinguish itself with the safest hospitals possible to promote continued growth in the expanding medical tourism market.

Medizone International announced in January 2014 that it was granted its fourth patent for its AsepticSure®. The United States Patent and Trademark Office (USPTO) issued US Patent number 8,636,951 titled “Bio-Terrorism Counteraction Using Ozone and Hydrogen Peroxide”.

On February 25, 2015, Medizone International posted a summary of peer-reviewed, published literature comparing the effectiveness of AsepticSure® in comparison to Xenex. The Company said that only AsepticSure® has demonstrated the ability to actually break the reinfection cycle in a healthcare setting. This was demonstrated at Belleville General Hospital in the Province of Ontario, Canada.

The demonstration at Belleville in which a ward that had averaged “one to two new MRSA infections a month” has now gone over a year without a new infection following a single AsepticSure® disinfection. Medizone believes this is strong evidence that when you kill 100 percent of the infective pathogen in a healthcare setting, you have broken the reinfection cycle.

Medizone International, Inc. (MZEI), closed Monday's trading session at $0.0838, up 8.83%, on 248,660 volume with 15 trades. The average volume for the last 60 days is 131,146 and the stock's 52-week low/high is $0.0701/$0.294.

Sigma Labs, Inc. (SGLB)

PennyStocks24 and Pennybuster reported earlier on Sigma Labs, Inc. (SGLB), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Sigma Labs, Inc. engages in the development and commercialization of manufacturing and materials technologies, and research and development (R&D) solutions. Through its wholly-owned subsidiary, B6 Sigma, Inc., Sigma Labs develops and engineers advanced, in-process, non-destructive quality inspection systems for metal-based additive manufacturing. In addition, it serves as an AM contract manufacturer. Sigma Labs is headquartered in Santa Fe, New Mexico.

The Company consists of top scientists and engineers from Los Alamos National Laboratory. It is a foremost developer of proprietary In-Process Quality Assurance™ (IPQA®) software for additive manufacturing. Sigma Labs centers on bringing novel and advanced materials and manufacturing technologies out of the nation's top National Labs and into the market to serve the aerospace, defense, biomedical, power generation, as well as general industrial sectors.

The Company has current contracts with Federal Government and private industry clients. These contracts are to develop technologies from their conception through the design, building, and testing of prototype systems through integrating sensing, software, materials, and manufacturing technology risk-reduction solutions.   

Its methodology will be to commercialize technologies via partnerships, joint development, and licensing with other firms. These technologies include its unique PrintRite3D® technology. This technology will allow metals parts to be built by 3D printing or additive manufacturing with fewer flaws and better properties.

In April 2014, Sigma Labs announced it signed a Technology Cooperation Agreement with Materialise NV of Leuven, Belgium. The agreement sets out the parties' intention to collaborate technically and commercially in the integration, production, and marketing of PrintRite3D® software-related products for metal-based additive manufacturing. In September 2014, Sigma Labs announced the formal release of its PrintRite3D® INSPECT™ quality assurance software.   

This month, Sigma Labs announced that it has become a Silver member of the America Makes consortium. It earlier announced that it was awarded an America Makes research project for In-Process Quality Assurance™ (IPQA®), with the objective of achieving high-volume AM production of aerospace components. It won its first contract under this award with GE Aviation, earlier this year. Additional contracts are anticipated from Honeywell Aerospace and Aerojet Rocketdyne, a unit of GenCorp. America Makes is the National Additive Manufacturing Innovation Institute (NAMII) headquartered in Youngstown, Ohio.

Sigma Labs, Inc. (SGLB), closed Monday's trading session at $0.12, up 7.14%, on 7,467,881 volume with 357 trades. The average volume for the last 60 days is 1,510,631 and the stock's 52-week low/high is $0.042/$0.1665.

Ekso Bionics Holdings, Inc. (EKSO)

Money Morning, Total Wealth, and CustomerService reported on Ekso Bionics Holdings, Inc. (EKSO), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Ekso Bionics Holdings, Inc. designs, develops, and commercializes exoskeletons, or wearable robots. Exoskeletons are ready-to-wear, battery-powered robots. They are strapped over the user's clothing, enabling individuals to achieve mobility, strength, or endurance not otherwise possible. These have an array of potential applications in the medical, military, industrial, as well as consumer markets. Ekso Bionics Holdings has its headquarters in Richmond, California.

Ekso Bionics Holdings has been accepted by the Center for Sensorimotor Neural Engineering (CSNE) as an industry partner. Ekso Bionics and CSNE are working jointly to enrich the human machine interface and enhance potential neural interface to create links between the nervous system and the outside world.

The Company’s lead product is Ekso™. Ekso™ has helped thousands of people living with paralysis take millions of steps not otherwise possible. Its Ekso™ is a robotic exoskeleton used for the rehabilitation of individuals with lower extremity weakness, paralysis or hemiparesis (weakness on one side of the body) owing to such neurological conditions as stroke, spinal cord injury or disease, and traumatic brain injury.

Ekso™ is a wearable bionic suit. It permits individuals with any amount of lower extremity weakness to stand up and walk over ground with a natural, full weight bearing, and reciprocal gait. Walking is attained via the user’s weight shifts to activate sensors in the device, which initiate steps. Battery-powered motors drive the legs, replacing deficient neuromuscular function.

Ekso Bionics has been awarded a P20 Exploratory Grant from the National Institutes of Health (NIH). This is to continue the development of an exoskeleton prototype for children. This work will be done in collaboration with the pediatric rehabilitation department at the UCSF Benioff Children's Hospital Oakland. This work will consist of Ekso Bionics developing a pediatric version of its Ekso GT™ robotic exoskeleton.

Ekso Bionics announced this past January that nine leading centers in Europe including SPZ Notwill in Switzerland, Institut Guttmann in Spain, and The Clinic for Spinal Cord Injuries in Hornbaek, Denmark (now part of Rigshospitalet and Glostrup Hospital), are participating in a clinical study to include approximately 70 participants. The study will examine how Ekso GT may improve general outcomes and reduce secondary complications, including pain and bowel and bladder dysfunction, typically associated with spinal cord injury (SCI). The expectation is that the study will run for 30 months with early findings expected in 2016.

Last week, Ekso Bionics Holdings announced that Ms. Amy Wendell, former Senior Vice President, Strategy and Business Development of Covidien, a global health care products company and manufacturer of medical devices and supplies, was elected to Ekso Bionics' Board of Directors. Since 1986, Ms. Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall.

Ekso Bionics Holdings, Inc. (EKSO), closed Monday's trading session at $2.01, up 3.61%, on 943,168 volume with 629 trades. The average volume for the last 60 days is 631,981 and the stock's 52-week low/high is $0.753/$3.53.

Solar Power, Inc. (SOPW)

Stock Oodles reported recently on Solar Power, Inc. (SOPW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Solar Power, Inc. {SPI Solar (SPI)} is a vertically-integrated photovoltaic solar developer. The Company provides its own brand of high-quality, low-cost distributed generation and utility-scale solar energy facility development services. SPI Solar has evolved from a photovoltaic (PV) solar manufacturer and developer, into a leading turnkey solar energy facility (SEF) developer. SPI Solar has its operating headquarters in Shanghai. It also has international operations in Asia, Europe and North America.

SPI delivers turnkey world-class photovoltaic solar energy facilities and turnkey residential solar solutions to its business, government, and utility customers. This runs the scale from project development, to project financing and to post-construction asset management. SPI Solar develops distributed generation SEFs to provide onsite electricity production for commercial and industrial enterprises.

In addition, SPI Solar develops utility-scale SEFs to provide electricity to power grids serving sizeable areas. Its strategy is to work as a vertically integrated, turnkey solar developer or EPC Contractor to design, engineer, and construct high-quality, low-cost photovoltaic SEFs for commercial and industrial enterprises.

SPI announced this past January that it entered into definitive agreements and closed the acquisition of Gonghe County Xinte Photovoltaic Co., Ltd. (Xinte), a PV project company established in China with limited liability and directly owned by TBEA Xinjiang Sunoasis Co., Ltd. (TBEA Sunoasis). SPI’s wholly-owned subsidiary, SPI Solar Power (Suzhou) Co., Ltd., closed the transaction to acquire all of the outstanding capital stock of Xinte from TBEA Sunoasis for a purchase price of RMB206.0 million (U.S. $33.1 million) in cash and factoring financing.

This month, SPI announced that its wholly-owned subsidiary, SPI Solar Japan GK (SPI Japan), entered into a definitive agreement to sell all of its interest in the land and project development rights for a 6.4 megawatt (MW) solar PV project in Susami City, Wakayama Prefecture. The sale is subject to a number of closing conditions. It is expected to close this month.

Additionally, this month, SPI announced that it entered into a definitive agreement to acquire 100 percent of the interest in the 6.02 megawatt (MW) solar projects called "Aerojet" in Rancho Cordova, California. The acquisition is subject to numerous closing conditions. This includes completion of satisfactory due diligence. Built in 2009 and 2010 by SPI, the Aerojet solar farms were the largest single-site industrial solar installation in California and amongst the largest in the U.S.at the time.

Xiaofeng Peng, Chairman of SPI, said, "We are excited to announce our proposed re-acquisition of the landmark Aerojet solar projects that helped build the California solar market into what it is today. Having these high-quality assets back within SPI will strengthen both our position in the US market and our growing global PV portfolio."

Furthermore, SPI operates a unique online energy e-commerce and investment platform, www.solarbao.com. This platform enables individual and institutional investors to buy innovative PV-based investment and other products.

Solar Power, Inc. (SOPW), closed Monday's trading session at $1.88, up 0.53%, on 122,165 volume with 48 trades. The average volume for the last 60 days is 203,539 and the stock's 52-week low/high is $0.1713/$2.95.

Health Discovery Corp. (HDVY)

TopPennyStockMovers, Wallstreetlivechat, FeedBlitz, AllPennyStocks, Stock Traders Chat, Stock Rich, BullRally, HotOTC, and Cool Penny Stocks reported earlier on Health Discovery Corp. (HDVY), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 2001, Health Discovery Corp. is a pattern recognition company. It employs advanced mathematical techniques to analyze significant amounts of data to uncover patterns that might otherwise be undetectable. The Company operates principally in the field of molecular diagnostics where such tools are vital to scientific discovery. Artificial intelligence (AI) and machine learning are terms sometimes used to describe pattern recognition tools. Health Discovery is based in Atlanta, Georgia.

The Company’s mission is to use its patents, intellectual expertise, and clinical partnerships mainly to identify patterns that can advance the science of medicine, and to advance the effective use of its technology in other varied business disciplines. These include the high-technology, financial, as well as healthcare technology markets.

Health Discovery’s primary asset is its intellectual property (IP), which includes advanced mathematical algorithms called Support Vector Machines (SVM) and Support Vector Machines along with Recursive Feature Elimination (RFE- SVM), and biomarkers that it discovered through applying its SVM and RFE- SVM techniques to complex genetic and proteomic data. Biomarkers are biological indicators or genetic expression signatures of certain disease states. Health Discovery’s IP is protected by many patents, which have been issued or are currently pending worldwide.

Health Discovery’s current commercialization efforts include utilization of its discoveries and knowledge to help develop diagnostic and prognostic predictive tests; licensing of the SVM and RFE- SVM technologies directly to diagnostic companies; and, the potential establishment of new ventures with domain experts in other fields where Health Discovery’s pattern recognition technology holds commercial promise. 

Mr. Vladimir Vapnik invented the SVM. It was refined into a more practical application by Ms. Isabelle Guyon. Both Mathematicians have provided major contributions to Health Discovery. It was Dr. Guyon's work for the Company that led to the discovery of genes associated with prostate cancer and a diagnostic test. Health Discovery invented some of the earliest SVM's, which are part of its patents. Furthermore, it has the first patent related to RFE- SVM (recursive feature elimination) in the world.

Health Discovery’s SVM technology outperforms even advanced statistical modeling methodologies including neural networks. SVMs can process infinite amounts of data and analyze the data to find separations and delineations high dimensionality. The Company markets its technology and related developmental expertise to prospects in the healthcare, biotechnology, and life sciences industries.

Health Discovery Corp. (HDVY), closed Monday's trading session at $0.0151, down 10.12%, on 601,900 volume with 18 trades. The average volume for the last 60 days is 116,170 and the stock's 52-week low/high is $0.0071/$0.039.

Cocrystal Pharma, Inc. (COCP)

PennyStocks Forever reported on Cocrystal Pharma, Inc. (COCP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cocrystal Pharma, Inc. is a biotechnology company developing novel antiviral therapeutics for human diseases. It merged in 2014 with Biozone Pharmaceuticals, Inc. Cocrystal Pharma announced in November 2014 the closing of its merger with RFS Pharma, LLC. RFS Pharma is a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.

Cocrystal Pharma has earlier received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK), and The Frost Group. OPKO Health and The Frost Group together own around 48 percent of Cocrystal Pharma. Cocrystal Pharma has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, Dengue Virus, the Norovirus, and others (it has identified a picomolar inhibitor of NS5a, another essential viral replication protein).

The Company concentrates on the discovery and development of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal Pharma employs innovative technologies and Nobel Prize winning expertise to create first- and best-in-class antivirals. The design of these technologies and its market-focused approach to drug discovery are to efficiently deliver small molecule therapeutics that are safe, effective, as well as convenient to administer.  
Cocrystal Pharma is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. Its Influenza, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals. The Company has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product. It employed its core platform technology to develop the in vitro test.

Cocrystal Pharma is developing drug candidates specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance. Selection of a lead compound for clinical development is planned to take place this year. Regulatory filings to commence clinical studies for influenza are planned for December of this year.

Cocrystal Pharma’s Hepatitis C program continued to make progress in Q2 2014. The Company has selected CDI-244 for development as a treatment for patients with Hepatitis C (HCV). Cocrystal plans regulatory filings to start clinical trials of CDI-244 this year.

Company scientists have made first-rate progress discovering potent inhibitors of the influenza endonuclease, an enzyme that is essential for viral genome replication. Selection of a lead compound for clinical development is planned to take place this year. Regulatory filings to commence clinical studies for influenza are planned for December 2015.

Cocrystal Pharma, Inc. (COCP), closed Monday's trading session at $1.17, down 0.85%, on 578,047 volume with 241 trades. The average volume for the last 60 days is 1,480,757 and the stock's 52-week low/high is $0.252/$1.53.

Cell MedX Corp. (CMXC)

SMS Penny Picks, Wall Street Beauties, WINNINGOTC, FatCat Stocks, Daily Stock Motion, Penny Stocks VIP, Penny Pick Insider, MyBestStockAlerts, Center Stage Stocks, Market Wire Stocks, SuperStockTips, Beacon Equity Research, Stock Preacher, Penny Stock Craze, InvestorSoup, Penny Stocks Finder, Gryphon Digest, StockHideout, Growing Stocks Reports, Michael Stone, Penny Stock Newsletter, PREPUMP STOCKS, Damn Good Penny Picks, and Penny Picks reported this month on Cell MedX Corp. (CMXC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Cell MedX Corp. is an early development stage company headquartered in Las Vegas, Nevada. It centers on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes through developing technologies to help manage the illness and related complications. Fundamentally, Cell MedX manufactures and distributes medical devices, which are powered by its proprietary, patented technology of low level current primarily for supporting chemical (pharmaceutical) treatments for diabetes. Moreover, via its wholly-owned subsidiary, Avyonce Cosmedics, Inc., Cell MedX engages in the resale and marketing of spa technology and equipment.

Cell MedX is at the vanguard of creating devices that treat chronic and acute conditions for clinical and self-management care. The Company is fashioning safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, called cellular medicine. Cell MedX’s goal is to release its first lineup of commercial products in early 2016. It will start with its flagship product named ‘e-balance’, which works to improve the efficacy of the client’s existing medication regimes.

The e-balance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance and blood pressure.

Cell MedX earlier received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. The pilot clinical discovery phase trial in two diabetic subjects occurred in January of this year. Its main goal was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending.

Today, Cell MedX announced further results of the continuing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. Ongoing metabolomic analyses of the samples have yielded more insights into the immediate metabolic alterations brought about by a single e-balance technology treatment. In addition to indications of increased sensitivity to insulin, glycolytic processes are also clearly upregulated. These new findings reveal enhanced transport and use of glucose during a treatment.

Cell MedX Corp. (CMXC), closed Monday's trading session at $0.28295, up 1.05%, on 193,216 volume with 69 trades. The average volume for the last 60 days is 55,140 and the stock's 52-week low/high is $0.25/$1.09.


The QualityStocks
Company Corner


Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.1199, up 99.50%, on 9,966 volume with 6 trades. The stock’s average daily volume over the past 60 days is 41,487, and its 52-week low/high is $0.06/$0.42.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International

Mobile Lads Begins Operating North American Shopping Network Simbadeals.com

Mobile Lads Purchases Majority of North American Shopping Network From Domark International

Sparta Commercial Services, Inc. (SRCO)

The QualityStocks Daily Newsletter would like to spotlight Sparta Commercial Services, Inc. (SRCO). Today, Sparta Commercial Services, Inc. closed trading at $0.07, up 11.11%, on 28,800 volume with 2 trades. The stock’s average daily volume over the past 60 days is 170,770, and its 52-week low/high is $0.0496/$1.25.

Sparta Commercial Services, Inc. (SRCO) is a New York-based technology company whose subsidiary, Specialty Reports, Inc., is a leader in developing, managing, and servicing custom mobile apps for small and medium sized businesses as well as for retail vehicle dealers, in addition to providing motor vehicle title history reports to dealers, insurance companies, financial institutions, consumers, and other interested parties. Sparta Commercial Services also offers and administers vehicle and capital equipment lease financing programs for municipalities.

iMobileApp.com develops and services customized mobile applications for powersports, automobile, recreation vehicle, marine, and agriculture equipment dealers as well as for racetracks, restaurants, liquor stores, schools and any other small to medium sized company. The iMobileApp allows businesses to stay in touch with their customers, to notify them of upcoming and ongoing promotions, special events, and provide them with the ability to view new and used inventory, communicate directly with the service department, and more. The mobile application is generated, packaged, and made available on-line, at no cost to the company's customers, through the Apple App Store and the Google Play Store.

The company also serves as a one-stop online source for various types of vehicle title history reports, including motorcycles, recreation vehicles, automobiles, light trucks, and commercial (heavy duty) trucks. Its online history report products include Cyclechex.com, a motorcycle vehicle title history report provider; RVchecks.com, a RV vehicle title history report provider; and CarVinReport.com, an automobile and light truck vehicle title history report provider, and TruckChex.com, a commercial (heavy duty) truck vehicle title history report provider.

In addition to consumers – both buyers and sellers – vehicle dealerships, insurance companies, financial institutions and others benefit from the information provided on these vehicle title history reports. The Specialty Reports, Inc. vehicle title history reports are featured online at NADAGuides.com, KBB.com and DMV.org, prominent online sources for pre-owned vehicle values and other important information for both buyers and sellers.

The company’s Municipal Lease Financing Program for local and/or state agencies throughout the country provides an economical way to finance essential equipment, from police motorcycles and cruisers to EMS equipment and busses, to virtually any type of equipment required. The lease purchase financing program receives considerable praise for its understanding of government acquisition procedures and its work with a wide range of vendors.

Sparta Commercial Services is an innovative and diversified company that has proven its ability to identify the needs and interests of its targeted markets, as well as develop products and services specifically designed to meet those needs and interests now and well into the future. With a full suite of offerings that address the challenges of the powersports, recreation, and auto industries, the company is well positioned to achieve strong future growth rates. Disclaimer

Sparta Commercial Services, Inc. Company Blog

Sparta Commercial Services, Inc. News:

iMobileApp's Customer Base Continues to Diversify

Sparta Commercial Reports Continued Sales Growth

iMobileApp's Customer Base Continues to Grow and Broaden

Inventergy Global, Inc. (INVT)

The QualityStocks Daily Newsletter would like to spotlight Inventergy Global, Inc. (INVT). Today, Inventergy Global, Inc. closed trading at $0.3996, up 2.46%, on 125,557 volume with 196 trades. The stock’s average daily volume over the past 60 days is 381,416, and its 52-week low/high is $0.353/$10.52.

Inventergy Global, Inc. (INVT) is an intellectual property (IP) licensing partner specializing in IP value creation. Led by industry veteran Joe Beyers, former head of global licensing for Hewlett-Packard, Inventergy identifies, acquires and licenses patented technologies to help market-leading technology companies monetize and achieve more value from their innovations.

With more than 100 years of combined experience and track record of handling more than $15 billion in IP and technology transactions, Inventergy’s team of professionals handle every aspect of the IP business, from valuation and branding through legal analysis, decision making and patent sales.

Inventergy partners with world-class, market-significant companies who may lack internal manpower, budget or other resources necessary to realize appropriate return-on-investment. Through collaborative, business-centered, and forward-thinking strategies, Inventergy is able to create portfolios with significant market potential and optimize the innovator’s overall return-on-investment.

The company has established a network of key industry relationships to complement its solid licensing model and growing portfolio of assets, which currently stands at more than 760 global patent assets. Inventergy pursues maturing telecommunications technologies already adopted in the marketplace and earning accretive value. Disclaimer

Inventergy Global, Inc. Company Blog

Inventergy Global, Inc. News:

Inventergy Announces $2.15 Million Common Stock Financing to Accelerate Licensing Operations

Inventergy Announces CEO & Chairman Joe Beyers to Present at IPBC Global 2015, San Francisco

Inventergy Announces Operational Restructuring of Its Product Businesses Designed to Improve Margins, Cash Flow and Earnings Growth

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.4285, off by 0.33%, on 164,977 volume with 54 trades. The stock’s average daily volume over the past 60 days is 110,657, and its 52-week low/high is $0.3401/$0.88.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Reports 2014 Year-End Financial Results and Provides Operational Update

STWA Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call

STWA Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.1831, up 1.67%, on 18,712 volume with 15 trades. The stock’s average daily volume over the past 60 days is 23,282, and its 52-week low/high is $0.13/$0.95.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Car Monkeys Group (CKMY)

The QualityStocks Daily Newsletter would like to spotlight Car Monkeys Group (CKMY). Today, Car Monkeys Group closed trading at $0.16, even for the day, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 1,449, and its 52-week low/high is $0.10/$5.00.

Car Monkeys Group (CKMY), via CarMonkeys.com, is one of the largest and fastest growing online cars, vans and SUV parts distributors in the United States. Founded in 2010, the Wyckoff, New Jersey-based company formerly was known as Delaine Corporation and changed its name to Car Monkeys Group in February 2015.

With access to hundreds of thousands of parts, Car Monkeys sells used, high-quality, low-mileage automotive parts to consumers, retailers, truck and car fleet owners and auto repair facilities looking for a wide range of vehicle makes and models. Customers have access to a Part Finder section that helps them easily navigate and quickly locate the right parts they need.

Striving to provide customers a quick, hassle-free and convenient shopping experience, all parts ordered through CarMonkeys.com ship from one of the company’s numerous distributors and auto dismantling centers straight to the customer or their mechanic. Advantages such as a five-year unlimited mileage warranty, zero shipping costs, and a generous return policy further contribute to the increasing popularity of the Car Monkeys brand.

Automotive recycling plays a substantial role in the preservation of natural resources and reduction of demand for landfill space. According to the Automotive Recyclers Association, approximately 95% of vehicles retired from use are processed for recycling, saving an estimated 85 million barrels of oil that would have been used to manufacture new or replacement parts. As a rapidly growing and trusted automotive recycling company, Car Monkeys is positioned as a leading player in the broader $22 billion North American automotive recycling industry. Disclaimer

Car Monkeys Group Company Blog

Car Monkeys Group News:

Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services

Car Monkeys Group (CKMY) is “One to Watch”

Car Monkeys Group (CKMY) Continues Growth as one of the Country’s Largest Online Automobile Parts Distributors

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.18, even for the day. The stock’s average daily volume over the past 60 days is 1,330 and its 52-week low/high is $0.06/$0.45.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview

Dominovas Energy Corp. Appoints International Business Professional to Board of Directors

Dominovas Energy and Delphi Sign MOU


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251